Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Illumina, Inc.
The annual J.P. Morgan Healthcare Conference includes presentations from many major medtech companies outlining their growth strategies and expectations for 2021. Here are some of the highlights from the first day of the meeting.
The emergence of multi-cancer blood tests for early detection is captivating investors and driving multi-billion-dollar acquisitions. Companies such as GRAIL, Thrive Earlier Detection and Guardant are predicting revolutionary change in the way cancer is diagnosed and treated. The biggest hurdle, however, may be coaxing health care systems and health insurers to join the revolution.
Medtechs took a long look at themselves as they rose to the challenges of COVID-19. How they responded, repurposed and regrouped to tackle the coronavirus was both sobering and uplifting. The lessons of 2020 must be integrated into the digitally-enabled health care systems of 2021 and beyond.
Device company M&A values reached $17.9bn in Q3, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $8.2bn.
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Nanotechnology, Chips, etc.
Drug Discovery Tools
- Other Names / Subsidiaries
- GenoLogics Life Sciences Software
- GRAIL Inc.
- Verinata Health
- Illumina Ventures